Amwell reports Q4 EPS ($2.77), consensus ($2.55)

Reports Q4 revenue $71.01M, consensus $66.57M. Total visits were 1.4M. “During 2024, we advanced our business in ways that put us much closer to unlocking the value of Amwell (AMWL) and advancing our mission to modernize healthcare with our unified platform,” said Ido Schoenberg, MD, chairman and CEO of Amwell. “Together with our partners at Leidos, we are successfully launching our full solution across the U.S. Military Health System, the most significant growth initiative in our history. We are also undertaking meaningful quality of revenue and margin initiatives that are resulting in steady, better-than-expected quarterly improvements in our adjusted EBITDA. We are successfully refining our business to deliver on the expectations of stakeholders, advancing us to generate positive cash flow during 2026, with a robust cash position.”